Eintrag weiter verarbeiten
| Zusammenfassung: | <jats:title>Abstract</jats:title> <jats:p>Hepcidin agonists are a new class of compounds that regulate blood iron levels, limit iron absorption, and could improve the treatment of hemochromatosis, β-thalassemia, polycythemia vera, and other disorders in which disrupted iron homeostasis causes or contributes to disease. Hepcidin agonists also have the potential to prevent severe complications of siderophilic infections in patients with iron overload or chronic liver disease. This review highlights the preclinical studies that support the development of hepcidin agonists for the treatment of these disorders.</jats:p> |
|---|---|
| Umfang: | 1790-1794 |
| ISSN: |
0006-4971
1528-0020 |
| DOI: | 10.1182/blood-2017-11-737411 |